247 search results for “anti-cancer drug steen” in the Staff website
-
Joesjka van der Steen
Universitair Facilitair Bedrijf
j.van.der.steen@ufb.leidenuniv.nl | +31 71 527 2727
-
Jeltje van der Steen
Administratief Shared Service Centre
j.van.der.steen@assc.leidenuniv.nl | +31 71 527 3179
-
Babet van Steen
Faculteit der Sociale Wetenschappen
b.c.m.van.steen@fsw.leidenuniv.nl | +31 71 527 2727
-
Dick van der Steen
ICT Shared Service Centre
d.c.van.der.steen@issc.leidenuniv.nl | +31 71 527 2727
-
Tamara van den Steen
Science
t.m.van.den.steen@lacdr.leidenuniv.nl | +31 71 527 2727
-
Jasper van der Steen
Faculty of Humanities
j.a.van.der.steen@hum.leidenuniv.nl | +31 71 527 1492
-
Bart van der Steen
Universitaire Bibliotheken Leiden
b.s.van.der.steen@library.leidenuniv.nl | +31 71 527 6338
-
Tommy van Steen
Faculty Governance and Global Affairs
t.van.steen@fgga.leidenuniv.nl | +31 70 800 9160
-
Training: alcohol- and drug use under students
Training for staff members
-
Hildert Bronkhorst
Science
h.bronkhorst@biology.leidenuniv.nl | +31 71 527 4964
-
Review on “Anticancer opportunities at every stage of chemokine function” is featured on the cover of TIPS
Last November, Dr. Natalia Ortiz, Martijn Bemelmans (MSc), and Prof. Laura Heitman published a review in Trends in Pharmacological Sciences (TIPS) on targeting the chemokine system in cancer (https://doi.org/10.1016/j.tips.2021.08.001). The review was written in collaboration with Prof. Tracy Handel…
-
Evani Lachmansingh
Science
e.t.lachmansingh@liacs.leidenuniv.nl | +31 71 527 2727
-
Alexander Kros
Science
a.kros@chem.leidenuniv.nl | +31 71 527 4234
-
Developing drugs with artificial intelligence
Developing new drugs is a difficult process. With the aid of artificial intelligence, Pharmaceutical scientist Xuhan Liu has developed methods that can help make drug design cheaper and faster. PhD defence on 15 February.
-
Peter Bouwman
Science
r.j.p.bouwman@lacdr.leidenuniv.nl | +31 71 527 6105
-
Oncode Accelerator launched: patients at the centre of innovative cancer drug development
Providing each cancer patient with the right treatment remains a challenge. Oncode Accelerator aims to change this by innovating the way we develop cancer treatments, thus ensuring the patient is at the heart of the process.
-
New potential drug suppresses chemotherapy induced neuropathic pain
Oncode Investigator Mario van der Stelt and his colleagues have discovered a new potential drug that suppresses chemotherapy induced neuropathic pain.
-
Giulia Callegaro
Science
g.callegaro@lacdr.leidenuniv.nl | +31 71 527 6105
-
Bob van de Water
Science
water_b@lacdr.leidenuniv.nl | +31 71 527 6223
-
Artificial intelligence as the co-pilot for drug discovery
There are more molecules that could conceivably be candidate drugs than there are stars in the universe. How can we ever efficiently identify those molecules? Professor of AI and Medicinal Chemistry, Gerard van Westen: ‘I’m going to use artificial intelligence as the co-pilot to make an automated search.’…
-
LACDR PhD Introductory course on Drug Research
Recently, we had the LACDR PhD Introductory course on Drug Research for starting PhD candidates. It was great to have this live event live in castle Oud Poelgeest, after two years of restrictions.
-
LACDR PhD Introductory course on Drug Research
This week, we had the LACDR PhD Introductory course on Drug. This is always a great opportunity for starting PhD candidates to get to know LACDR, CHDR, the Clinical Pharmacology department of LUMC and the embedding of the institute in the BioSciencepark as a whole.
-
PhD Introductory Course on Drug Research
At the end of February, we had the PhD Introductory Course on Drug Research for starting PhD candidates from LACDR. This 3-days event took place at Castle Oud Poelgeest, a great location to be completely out of the work environment. We welcomed 30 PhD candidates, with whom we had an inspiring and…
-
LACDR PhD introductory course on drug research
Due to the corona pandemic and the uncertainty of the circumstances end of January 2022, is decided to postpone the LACDR PhD introductory course.
-
Laura Heitman
Science
l.h.heitman@lacdr.leidenuniv.nl | +31 71 527 4558
-
LACDR PhD Introductory course on Drug Research
The PhD introductory course will take place on 30 May, 31 May and 1 June 2022 in castle Oud Poelgeest. We are very happy that it will be a live event (as it stands now).
-
Willem Jespers appointed Assistant Professor AI & Structure Based Drug Discovery
Willem Jespers started his position as Assistant Professor in the group of Prof. G.J.P. van Westen on June 1st, a short introduction below:
-
Countering nerve pain caused by chemotherapy with new drug
Nerve pain is one of the most common side effects of chemotherapy. It is therefore one of the biggest reasons for cancer patients to stop treatment early. Darcy Reynolds worked on new drug candidates against this pain during her bachelor's thesis. She developed a new series of molecules that increase…
-
Promising new technique to treat cancer receives NWO grant
Biological chemist Nathaniel Martin and his team received an NWO grant to examine how blocking a specific enzyme in our body, NNMT, could be helpful in the treatment of some cancers. Trials with mice have been promising, and together with the Netherlands Cancer Institute, Martin wants to take the next…
-
Mario van der Stelt
Science
m.van.der.stelt@chem.leidenuniv.nl | +31 71 527 4768
-
Gerard van Westen
Science
gerard@lacdr.leidenuniv.nl | +31 71 527 3511
-
Eline Dekeyster
Faculteit der Sociale Wetenschappen
e.a.g.dekeyster@fsw.leidenuniv.nl | +31 71 527 2727
-
Roxanne Kieltyka
Science
r.e.kieltyka@chem.leidenuniv.nl | +31 71 527 4441
-
Madeline Kavanagh
Science
m.e.kavanagh@lic.leidenuniv.nl | +31 71 527 3527
-
Review paper on the potential impact drug-metabolizing enzymes on brain exposure
PhD candidate Mengxu Zhang (Division of Systems Pharmacology and Pharmacy) published a comprehensive and important review on “The potential impact of CYP and UGT drug-metabolizing enzymes on brain target site drug exposure” in Drug Metabolism Reviews.
-
Growth Fund invests many millions in faster and more sustainable (cancer) drug development
On 14 April, the National Growth Fund awarded million euros in grants to two consortia in which Leiden's science faculty is involved. Pharma-NL will receive 80 million euros and Oncode-PACT 325 million euros. Pharma-NL wants to make medicines available to the patient faster and more sustainably. Oncode-PACT…
-
Universiteit Leiden Announce Collaboration to Develop Advanced Polyaminoacid Drug Delivery Systems
Polypeptide Therapeutic Solutions (PTS), a leader in the design, development and custom manufacturing of polyamino-acid based delivery systems for therapeutic drugs and the Leiden Academic Centre for Drug Research (LACDR) today announced a research collaboration to develop advanced drug delivery systems…
-
Arteriosclerosis and drug discovery: two young researchers win Krijn Rietveld Award for innovative research
One discovered that arteriosclerosis resembles an autoimmune disease, while the other developed a system to aid in the search for new medications. For these achievements, Marie Depuydt and Jurren de Groot were awarded the Krijn Rietveld Memorial Innovation Award on the evening of Tuesday 4 June.
-
From lab discovery to a new drug: the Venture Challenge makes it possible
A breakthrough from the PhD research of medical chemist Elmer Maurits may help patients with autoimmune diseases and blood cancer in the future. But bringing a discovery from the lab to the clinic is not so easily done. Thanks to NWO's Venture Challenge, Maurits and his team will receive ten weeks of…
-
Anthe Janssen
Science
a.p.a.janssen@lic.leidenuniv.nl | +31 71 527 4362
-
Joost Batenburg
Science
k.j.batenburg@liacs.leidenuniv.nl | +31 71 527 6985
-
Coen van Hasselt
Science
coen.vanhasselt@lacdr.leidenuniv.nl | +31 71 527 3266
-
Skin researcher calls for multidisciplinary collaboration: ‘I want to pool expertise’
In dermatology, there should be a high level of multidisciplinary collaboration among institutes and specialists, Professor of Translational Dermatology, Robert Rissmann, will say in his inaugural lecture on 8 July. He is building an infrastructure that will put pre-clinical and clinical skin research…
-
How Oncode-PACT is bringing new cancer medicines closer with 325 million in Growth Fund money
How can you ensure that more experimental drugs reach the finish line? At the moment, only one in twenty cancer drugs that are tested on humans makes it to the market. This is an enormous loss for patients and society. With a grant from the National Growth Fund, Oncode-PACT aims to efficiently select…
-
for effective application of a new revolutionary cholesterol lowering drug resides in a 30 year old Leiden Patent
‘’ And then the world changed forever ,welcome to the future’’. These are the words that Kausik Ray (President of the European Atherosclerosis Society) spoke when the worldwide first dose of inclisiran, a novel SiRNA based cholesterol lowering agent, was administered at the Cardiology lipid clinic at…
-
How to develop cancer drugs with less side effects
Lecture, Tuesday Talks: Science Insights
-
Sebastian Pomplun
Science
s.j.pomplun@lacdr.leidenuniv.nl | +31 71 527 4651
-
Is a cancer pill a matter of time?
A cancer pill, preferably without severe side effects, is something we’d all welcome. Is it a matter of time before such a pill is a reality? We put this question to three Leiden researchers and asked how they themselves are contributing to new cancer treatments.
-
From discovery to business: 'In the lab, we often don't realise that we are working to help an immense number of patients'
'It gave our team a big boost to hear that our work was valuable,' says medical chemist Elmer Maurits about the moment they won the Venture Challenge. With their company Iprotics, they want to develop a drug that can better treat patients with autoimmune diseases and blood cancers. 25,000 euros of prize…
-
RARE-NL: LUMC joins consortium to find treatments for rare diseases
RARE-NL, a new collaboration between university hospitals, hopes to find treatments for rare diseases. Professor Teun van Gelder is representing the LUMC in the initiative.